Abstract: Arc flash mitigation devices are employed to protect personnel during maintenance of photovoltaic inverters. During normal operation, an alternating current (AC) output of a photovoltaic inverter is coupled to a low voltage winding of a step up transformer through a bus-bar (e.g., an electrically conductive interconnect), which has higher current rating than a fuse. During maintenance, the bus-bar is replaced with the fuse. The fuse may be employed in conjunction with a switch. The switch may be a disconnect switch that places the bus-bar in parallel with the fuse during normal operation, and decouples the bus-bar from the fuse during maintenance. The switch may also be a transfer switch that places either the bus-bar or the fuse in series with the AC output of the photovoltaic inverter and the low voltage winding of the step up transformer.

Abstract: Arc flash mitigation devices are employed to protect personnel during maintenance of photovoltaic inverters. During normal operation, an alternating current (AC) output of a photovoltaic inverter is coupled to a low voltage winding of a step up transformer through a bus-bar (e.g., an electrically conductive interconnect), which has higher current rating than a fuse. During maintenance, the bus-bar is replaced with the fuse. The fuse may be employed in conjunction with a switch. The switch may be a disconnect switch that places the bus-bar in parallel with the fuse during normal operation, and decouples the bus-bar from the fuse during maintenance. The switch may also be a transfer switch that places either the bus-bar or the fuse in series with the AC output of the photovoltaic inverter and the low voltage winding of the step up transformer.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: The invention provides systems and methods for managing mobile devices of supported by different platforms. In some embodiments, the invention provides this management capability by utilizing one or more agents or modules native to the platforms themselves to provide interaction with individual mobile. In some embodiments, the invention provides an abstraction layer by which management tasks or other functions relating to mobile devices of different types may be generally defined and translated for application to mobile devices supported by different platforms. In some embodiments, the invention utilizes existing organizational structure of an enterprise or organization to define management permission for mobile device administrators and end users as well as to define policy configuration schemes for mobile devices. In some embodiments, the invention tracks the lifecycle of mobile devices within an enterprise or organization as assets within the organization.

Abstract: The present inventors have surprisingly found that rivaroxaban of formula I can be prepared in a one-pot process, in high purity and with high yield, by reacting 5-chlorothiophene-2-carboxylic acid or a salt thereof with a sulfonylating agent to produce a sulfonyl ester intermediate, which is then condensed with 4-[4-[(SS)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morjJholine-3-one or an acid addition salt thereof to produce rivaroxaban.

Abstract: The present invention relates to processes for the preparation of 4?-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3?-methoxyacetophenone and intermediates thereof. The present invention also provides a process for purifying 4?-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3?-methoxyacetophenone to obtain the purity greater than about 98.0 area % to about 99.0 area % as measured by HPLC, preferably greater than about 99.0 area % to about 99.5 area %, more preferably greater about 99.5 area % to about 99.9 area %. individual impurities lower than about 0.15 area %, preferably lower than about 0.1% and total impurities lower than about 0.5 area % by HPLC.

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.

Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Abstract: A process for preparation of 4-fluoro-?-[2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzene butane amide also known as a diketone intermediate of atorvastatin, completely devoid of impurities 3,4-difluoro-?-[2-methyl-1-oxopropyl]-?-oxo-n-?-diphenylbenzene butane amide; methyl, 2{-2[-(4-fluorophenyl)-2-oxo-1-phenylethyl)]}-4-methyl-3-oxo pentanoate; 1,4-bis(4-fluorophenyl)-2,3-diphenylbutane-1,4-dione, 1-(4-fluorophenyl)-2-phenyl ethanone; 1-(4-fluorophenyl)-2-phenyl ethanone and containing about 0.05% or less of 2-methyl-1-oxopropyl]-?-oxo-N-?-diphenylbenzene butane amide. In that process the said diketone intermediate of formula 1 is obtained by maintaining temperature ?25° C. to 50° C. during Friedel-Crafts acylation, in situ halogenation of formula II in presence of a solvent and nucleophilic substitution from a compound of formula III with formula IV in presence of a base.

Abstract: The present invention provides 4-Aza-2,3-didehydropodophyllotoxin compound of general formula A (4a-4z and 4aa-4ae) as useful potential antitumour agents against human cancer cell lines. The present invention further provides a process for the synthesis of 4-Aza-2,3-didehydropodophyllotoxin compounds (4a-4z and 4aa-4ae).

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.

Abstract: The invention provides systems and methods for managing mobile devices of supported by different platforms. In some embodiments, the invention provides this management capability by utilizing one or more agents or modules native to the platforms themselves to provide interaction with individual mobile. In some embodiments, the invention provides an abstraction layer by which management tasks or other functions relating to mobile devices of different types may be generally defined and translated for application to mobile devices supported by different platforms. In some embodiments, the invention utilizes existing organizational structure of an enterprise or organization to define management permission for mobile device administrators and end users as well as to define policy configuration schemes for mobile devices. In some embodiments, the invention tracks the lifecycle of mobile devices within an enterprise or organization as assets within the organization.

Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: A computer implemented method, apparatus, and computer-usable program product for exchanging data using data transformation are provided. A first data binding component receives data from a function selector. A set of data bindings capable of invocation by the first data binding component is available. The function selector determines a content type associated with the data. The first data binding component receives the data and the content type from the function selector. The first data binding component invokes a data binding corresponding to the content type from the set of data bindings to transform the data into a data object. The data object has an object name. A target application is determined based on the object name, and the data object is then routed to a target application.

Abstract: The present invention provides a reduced dose oral pharmaceutical composition comprising mixture of nanoparticulate fenofibrate and micronized fenofibrate and one or more pharmaceutically acceptable excipients.